Tolerogenic Fibroblasts ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05080270 (ClinicalTrials.gov) | September 21, 2020 | 5/10/2021 | Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis | Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis | Biological: Tolerogenic Fibroblasts | FibroBiologics | NULL | Completed | 18 Years | 55 Years | All | 5 | Early Phase 1 | Mexico |